The UK is taking a bold step towards the future of medicine and advanced technology, with the UK Space Agency awarding new research contracts to three British companies to explore manufacturing in space. The move signals a growing ambition to use the unique conditions of Low Earth Orbit to produce materials and pharmaceuticals that are difficult, costly, or impossible to make on Earth.
For the UK and its global diaspora following science, technology and innovation back home, this investment highlights how space is no longer just about rockets and exploration, but about real-world solutions that could transform healthcare, communications and high-tech industries worldwide.
The projects will explore how microgravity, natural vacuum conditions and extreme temperatures in orbit can be harnessed to create next-generation products. Together, the studies support in-orbit servicing, assembly and manufacturing, known as ISAM, which the government has identified as a priority area for economic growth, national security and long-term leadership in the global space economy.
Each company will investigate technical feasibility, mature critical technologies and develop realistic routes to commercial markets, ensuring the research delivers benefits back on Earth.
Speaking on the investment, Space Minister Liz Lloyd said space innovation is about improving everyday lives, not just exploration. She explained that by leveraging space conditions, British companies are pushing boundaries in the development of life-saving medicines and advanced materials that will power future technologies. The government’s backing, she added, is about securing high-value jobs and positioning the UK as a global leader in space manufacturing.
One of the contracts has been awarded to BioOrbit Ltd, which will design an end-to-end mission to manufacture pharmaceuticals in microgravity. Space conditions allow protein crystals to form more perfectly and consistently than on Earth, potentially enabling advanced cancer treatments that could be taken at home. BioOrbit is already working with regulators to ensure drugs produced in space can be commercialised under the same standards as Earth-based medicines.
Another study, led by Space Forge Ltd, will explore how semiconductor seed crystals could be produced commercially in orbit. These materials could significantly improve the efficiency, reliability and power of high-performance electronics used in telecommunications, data centres, electric vehicle charging and emerging technologies such as quantum computing. The company says the project builds on successful tests already carried out on its ForgeStar-1 platform.
The third contract has gone to OrbiSky Ltd, which will design a payload to manufacture ZBLAN fluoride glass in microgravity. This specialist optical fibre can transmit light with dramatically lower signal loss than traditional fibres, with major implications for faster telecommunications and more advanced medical imaging technologies.
Dr Paul Bate, Chief Executive of the UK Space Agency, said the investment positions the UK to capture entirely new markets while delivering tangible benefits back on Earth. From improved medicines to more efficient electronics, he said the studies reflect the government’s ambition to lead in one of the most exciting frontiers of modern technology.
The funding is jointly supported by the UK Space Agency’s Sustainability and ISAM programme and its Unlocking Space initiative, which focuses on removing barriers to growth across the UK space sector. This includes encouraging public and private sector demand for space-based services and supporting the commercialisation of products made in orbit, particularly in pharmaceuticals and advanced manufacturing.
Industry leaders involved in the projects say the work could be transformational. BioOrbit’s CEO, Dr Katie King, described space-manufactured pharmaceuticals as a potential world first that could change lives globally. Space Forge’s CEO, Josh Western, said the contract demonstrates the UK’s serious commitment to innovation, while OrbiSky’s CEO, Sylvester Kaczmarek, said the research marks a major step towards UK-led markets in space manufacturing with clear benefits for healthcare and communications.
As countries compete for leadership in the new space economy, these contracts underline the UK’s intent to move beyond launch capability and into high-value manufacturing in orbit. For the diaspora watching Britain’s scientific direction, the message is clear: space is becoming a workplace, not just a destination, and its impact may soon be felt in hospitals, homes and digital infrastructure around the world.